NEWS CENTER

Position:

Group Announcement

Media reports

Group News

Good news keeps coming! Shijiazhuang No.4 Pharmaceutical Group’s specialty active pharmaceutical ingredient, rosuvastatin calcium, has been approved.

Category:

Group Announcement

Time：2022-06-23

On June 23, the active pharmaceutical ingredient—rosuvastatin calcium—submitted by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Four Pharmaceutical Group, was approved by the National Medical Products Administration and has been registered as an active pharmaceutical ingredient for use in marketed formulations.

Good news keeps coming! Shijiazhuang No.4 Pharmaceutical Group’s specialty active pharmaceutical ingredient, rosuvastatin calcium, has been approved.

On June 23, the active pharmaceutical ingredient—rosuvastatin calcium—submitted by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Fourth Pharmaceutical Group, was approved by the National Medical Products Administration and registered as an active pharmaceutical ingredient for use in marketed formulations. This is the eighth special API variety that Shijiazhuang Fourth Pharmaceutical Group has obtained production approval for this year since implementing its “API + Finished Dosage Form” product strategy.

It is understood that rosuvastatin calcium is primarily used for the treatment of primary hypercholesterolemia or mixed dyslipidemia. Previously, the group had already obtained drug registration approvals from the National Medical Products Administration for two specifications of rosuvastatin calcium tablets (5 mg and 10 mg).

Over the past two years, Shijiazhuang No.4 Pharmaceutical has aligned its innovation chain with the industrial chain. The company’s R&D investment now accounts for nearly 10% of its main business revenue. Thanks to continuous optimization of its research system and talent development initiatives, its scientific and technological innovation has entered a period of concentrated “harvest,” strongly propelling the company onto the fast track of innovative development. As of now, this year alone, the company has been approved for 21 new product projects covering both finished dosage forms and active pharmaceutical ingredients—averaging more than three per month. The number and efficiency of its specialty generic drug and API development rank among the top in the domestic industry, providing strong support for the company’s move toward the high end of the value chain.

Keywords:

Good news! Shijiazhuang No.4 Pharmaceutical’s peritoneal dialysis solution product has become the first to receive approval for consistency evaluation.

Shijiazhuang Sihua Pharmaceutical’s Bunan Seline Tablets, Acetaminophen Mannitol Injection, and Levofloxacin Injection—three distinctive new products—were approved on the same day.

Good news! Shijiazhuang No.4 Pharmaceutical’s peritoneal dialysis solution product has become the first to receive approval for consistency evaluation.

Shijiazhuang Sihua Pharmaceutical’s Bunan Seline Tablets, Acetaminophen Mannitol Injection, and Levofloxacin Injection—three distinctive new products—were approved on the same day.